THE WOODLANDS, Texas, Nov. 30, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, announces that Dr. Albert Yen and Dr. Stanley Appel, Chairman of its Scientific Advisory Board, will be presenting at the International Symposium on ALS/MND on Friday, December 3rd in Philadelphia, PA. Dr. Yen will be discussing preliminary results of the collaborative efforts between Baylor College of Medicine and Power3 Medical utilizing the NuroPro(TM) as a tool in the early stage assessment and diagnosis of ALS.
Dr Yen's presentation entitled, "Serum protein biomarkers for identification of patients with ALS" will reveal, for the first time, one of the protein biomarkers used in the Company's NuroPro(TM) blood test. The test involves monitoring the concentration of 9 proteins in blood serum to detect and distinguish among Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease.
The International Symposium on ALS/MND is a unique annual event which brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields.
According to Dr. Ira Goldknopf, Chief Scientific Officer, "We believe that the analysis of 9 protein biomarkers in blood serum provides for a highly sensitive diagnostic tool for the early detection of Neurodegenerative diseases. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms. The ongoing clinical validation of the NuroPro(TM) has shown great promise as a tool for assessment of neurodegenerative disease."
For further information on the NuroPro(TM) please view the Company's Flash movie at http://power3medical.com/flash/nuropro.swf. More information regarding the symposium can be found by visiting www.mndassociation.org/full-site/symposium/call-index.htm.
About Power3 Medical Products, Inc.
Power3 Medical Products, www.Power3Medical.com, is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.